Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson’s Disease

Table 2

PDQ-8, VAS-pain, and CGI-S scores at baseline and after 3 months of months of nightly treatment with rotigotine transdermal patch in the efficacy population ().

Assessment scale	Mean ± SD score
	Baseline	EOT
PDQ-8	23.8 ± 18.6	18.2 ± 17.7
VAS-pain	3.2 ± 2.5	2.3 ± 2.4
CGI-S	3.7 ± 0.6	3.5 ± 0.7

versus baseline.
CGI-S, Clinical Global Impression of Severity; EOT, end of treatment; PDQ-8, short-form Parkinson’s Disease Questionnaire; SD, standard deviation; VAS, visual analogue scale.